期刊文献+

肿瘤血管生成相关因子CD105、 EphA2及其配体EphrinA1在喉鳞状细胞癌中的表达及意义 被引量:5

Expressions of angiogenesis-related factors: CD105, EphA2 and EphrinA1 in laryngeal squamous cell carcinoma and clinical implication
原文传递
导出
摘要 目的 探讨喉鳞状细胞癌(squamous cell carcinoma,SCC)中Endoglin(CD105)、促红细胞生成素产生肝细胞受体A2 (erythropoietin-producing hepatocyte receptor A2,EphA2)及其配体EphrinA1蛋白的表达及意义.方法 采用免疫组化SP法检测76例喉SCC和25例喉癌旁组织(adjacent normal laryngeal tissues)中CD105、EphA2及其配体EphrinA1的表达情况,分析它们与喉SCC患者临床病理因素的关系及对喉SCC预后判断的价值.应用SPSS 17.0统计软件包对数据进行分析,计数资料采用x2检验及Fisher精确检验.结果 喉SCC中以CD105标记的微血管密度(microvessel density,MVD)为10.33±2.29,大于喉癌旁组织(1.20 ±1.04),差异有统计学意义(t=18.732,P<0.05).CD105标记的MVD的表达与喉SCC的T分级、组织学分级、临床分期、淋巴结转移、是否复发有关(F值分别为5.34、4.79、5.36,t值分别为-2.70、2.25,P值均<0.05).EphA2、EphrinA1蛋白表达的阳性率在喉SCC分别为78.95% (60/76)、81.85% (62/76),大于喉癌旁组织的40.00%(10/25)、44.00% (11/25),差异有统计学意义(x2值分别为13.41、13.26,P值均<0.05).EphA2蛋白表达与喉SCC的组织学分级、T分级、临床分期、淋巴结转移、是否复发有关(x2值分别为6.25、14.60、15.11、8.52、5.54,P值均<0.05).EphrinA1蛋白表达与喉SCC的淋巴结转移、T分级、临床分期、是否复发有关(x2值分别为6.44、12.28、16.78、6.44,P值均<0.05).CD105、EphA2和EphrinA1蛋白表达两两之间均呈正相关(r值分别为0.72、0.74、0.64,P值均<0.05).生存分析显示,CD105、EphA2、组织学分级、淋巴结转移、临床分期、有无复发是患者预后的独立影响因素(P值均<0.05).结论 喉SCC中CD105与EphA2、EphrinA1蛋白的表达两两之间呈正相关,三者均促进喉SCC的发生、恶性发展,提示不良预后,联合检测三者的表达有助于喉SCC的诊断及预后判断. Objective To investigate the expressions of endoglin (CD105),erythropoietinproducing hepatocyte receptor A2 (EphA2) and its ligand ephrinA1 proteins in laryngeal squamous cell carcinoma (LSCC) and the relationship between their expressions and the clinicopathological factors of LSCC.Methods The expressions of CD105,EphA2 and EphrinA1 proteins were detected with immunohistochemical staining in LSCC in 76 cases and adjacent normal laryngeal tissues (ANLT) (S-P) in 25 cases.SPSS 17.0 software was used to analyze the data.Results The mean microvessel density (MVD) value marked by CD105 staining in LSCC was 10.33 ± 2.29,which was significantly higher than that in ANLT(1.20 ± 1.04,t =18.732,P 〈 0.05).The CD105-MVD was correlated with T stage,histological grading,clinical stage,lymph node metastasis,recurrence and prognosis in LSCC (F value was 5.34,4.79,5.36,t value was-2.70,2.56,all P 〈 0.05).The positive expression rates of EphA2 and EphrinA1 in LSCC were 78.95% (60/76),and 81.85% (62/76),which were respectively significantly higher than 40% (10/25) for EphA2 expression and 44% (11/25) for EphrinA1,expression in ANLT (x2 value was 13.41,13.26,both P 〈 0.05).EphA2 expression was correlated with histological grading,T stage,clinical stage,lymph node metastasis,recurrence and prognosis in LSCC (x2 value was 6.25,14.60,15.11,8.52,5.54,all P 〈 0.05).EphrinA1 expression was correlated with T stage,clinical stage,lymph node metastasis,recurrence and prognosis in LSCC (x2 value was 6.44,12.28,16.78,6.44,all P 〈 0.05).The expressions of CD105,EphA2 and EphrinA1 were positively correlated with each other r value was 0.72,0.74,0.64,all P 〈 0.05.Survival analysis indicated that the expressions of CD105 and EphA2,histological grading,lymph node metastasis,clinical stage and recurrence were independent factors for tumor prognosis in LSCC (P 〈 0.05).Conclusions The expressions of CD105,EphA2 and EphrinA1 protein were positively correlated with each other in LSCC.They may play important roles in the tumorigenesis,malignant progression and poor prognosis of LSCC.
作者 苏娟 吉晓滨 谢景华 李雯 Department of Otorhinolaryngology Guangzhou First People's Hospital Guangzhou China(Su J, Ji XB, Xie JH Department of Pathology, Guangzhou First People's Hospital, Guangzhou 510180, China (Li)
出处 《中华耳鼻咽喉头颈外科杂志》 CAS CSCD 北大核心 2016年第12期929-936,共8页 Chinese Journal of Otorhinolaryngology Head and Neck Surgery
基金 基金项目:广东省科技厅产业技术研究与开发资金计划项目(20128031800340) 广州市科技和信息化局社会发展应用基础研究专项(2013J4100024)
关键词 喉肿瘤 鳞状细胞 免疫组织化学 新生血管化 病理性 EPHA2 EPHRINA1 Laryngeal Neoplasms Carcinoma, squamous Cell Immunohistochemistry Neovascularization, pathologic EphA2 EphrinA1
  • 相关文献

参考文献4

二级参考文献36

  • 1李丙华,徐娅苹.CD_(105)标记微血管密度与喉癌临床病理特征相关性[J].中国耳鼻咽喉头颈外科,2004,11(6):343-345. 被引量:5
  • 2赵彤,朱梅刚,黄宗义,张亚历,张素娟,李梅芳.肺癌癌基因蛋白产物同步检测的对比分析[J].癌症,1995,14(1):13-15. 被引量:54
  • 3谷化平,冯和平,徐志勇,苏红.免疫组化在恶性黑色素瘤诊断中的作用[J].中国肿瘤临床,1996,23(8):599-600. 被引量:4
  • 4刘宏斌,杨其昌,陈莉,季晓华,沈屹.乳腺癌中CD105的表达及其预后意义[J].南通大学学报(医学版),2006,26(6):435-437. 被引量:1
  • 5Rosai J.阿克曼外科病理学[M].9版.北京:北京大学医学出版社,2006:625-9.
  • 6Weider N.Current pathologic methods for measuring intratumoral microvessel density with breast carcinoma and other solid tumors[J].Breast Cancer Res Treat,1995,36(2):169-80.
  • 7Li C,Issa R,Kumar P,et al.CD105 prevents apoptosis in hypoxic endothelial cells[J].J Cell Sci,2003,116(13):2677-85.
  • 8Akagi K,Ikeda Y,Sumiyoshi Y,et al.Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development[J].Surgery,2002,131(s1):109-13.
  • 9Saad R S,El-Gohary Y,Memari E,et al.Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma[J].Hum Pathol,2005,36(9):955-61.
  • 10Matsuno F,Haruta Y,Kondo M,et al.Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies[J].Clin Cancer Res,1999,5(2):371-82.

共引文献1373

同被引文献46

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部